RxDoctor Payments Data

Steven Bellows

Neurology · Houston, TXNPI 1821415118

Payments from drug & device makers

$503,451in general payments, 2019–2025

Across 114 payments — averaging $4416.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sage Therapeutics, LLC$214K
  • AbbVie$126K
  • Takeda Pharmaceuticals U.S.A., Inc.$88K
  • H. Lundbeck A S$54K
  • Boston Scientific$20K
  • Medtronic$966
  • plus $1K from 7 others
$1,143in research payments, 2019–2025

Across 10 payments — averaging $114.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K

What the payments were for

  • Speaking & faculty fees$2601%
  • Grants$20,00089%
  • Travel & lodging$310%
  • Food & beverage$2,1089%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503,451 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$288,114
Medicare patients
314
Services billed
28,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine88$727,736
RytaryCarbidopa/Levodopa105$185,176
NuplazidPimavanserin Tartrate27$178,922
GocovriAmantadine Hcl20$107,426
Carbidopa-LevodopaCarbidopa/Levodopa734$33,333
NeuproRotigotine14$25,634
MyrbetriqMirabegron34$24,791
Rivastigmine71$16,806
LinzessLinaclotide11$8,537
Carbidopa-Levodopa ErCarbidopa/Levodopa187$6,611
Entacapone28$5,841
Atomoxetine Hcl19$4,412
Rasagiline Mesylate21$4,176
Primidone84$4,035
Pramipexole DihydrochloridePramipexole Di-Hcl35$3,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$164$727,73688 claims
Acadia Pharmaceuticals IncNuplazid$71$178,92227 claims
AbbVieLinzess$125,522$8,53711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →